3.3.2. Baseline Serum Creatinine and Plasma CRP Values Define a Subset of NP001-Treated ALS Patients Whose Loss in VC over the 6-Month Study Is Markedly Slowed vs. Placebo. The gene discussed is CRP; the disease is amyotrophic lateral sclerosis.